AG
PAND

Artal Group’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Artal Group’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-145,000
Closed -$1.66M – 159
2020
Q3 		$1.66M Buy
+145,000
New +$2.48M 0.04% 122

Other funds holding PAND

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Artal Group's PAND Position: Q4 2020 in Review

Artal Group sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q4 2020, closing a stake of 145,000 shares — an estimated $1.66M sold.

Artal Group first reported a position in PAND in Q3 2020 and held it in 1 quarter. The position peaked at $1.66M in Q3 2020. 48 funds tracked by Wall St. Rank hold PAND as of Q4 2020.

  • Artal Group reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Artal Group sold 145,000 Pandion Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $1.66M.
  • Artal Group first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Artal Group's Pandion Therapeutics Inc. Common Stock position peaked at $1.66M in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.